Physician profile
Maureen Li
NPI 1346359387
$16,028.49
in general payments reported to CMS, 2019-2025
74 companies · $3,517 in 2025
The $3,517 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,999 · 2020: $1,460 · 2021: $1,312 · 2022: $1,238 · 2023: $1,415 · 2024: $1,087 · 2025: $3,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,896 · Education: $108 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,895.69 |
| Education | $107.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,581.96 | 2019-2025 | |
| Ucb, INC. | $1,189.80 | 2019-2025 | Fintepla, Zilbrysq, Rystiggo |
| Abbvie INC. | $1,016.20 | 2019-2025 | |
| Lilly USA, LLC | $704.61 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Sk Life Science, INC. | $611.93 | 2020-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $572.12 | 2019-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $547.42 | 2019-2025 | Ajovy, Austedo Xr |
| Biogen, INC. | $530.47 | 2019-2025 | Vumerity, Leqembi, Skyclarys |
| Eisai INC. | $530.42 | 2019-2025 | |
| Allergan, INC. | $521.40 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $512.97 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Novartis Pharmaceuticals Corporation | $496.29 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $442.74 | 2019-2025 | Nuplazid |
| Neurelis, INC. | $411.82 | 2020-2025 | Valtoco |
| Ipsen Biopharmaceuticals, INC | $337.95 | 2019-2021 |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.